A5057420179- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Lesions and Carcinomas
- Medical Imaging Techniques and Applications
- Advanced Breast Cancer Therapies
- Cancer Risks and Factors
- Radiomics and Machine Learning in Medical Imaging
- Estrogen and related hormone effects
- Global Cancer Incidence and Screening
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Cancer-related Molecular Pathways
- Cancer Diagnosis and Treatment
- Cancer Cells and Metastasis
- Science, Research, and Medicine
- MRI in cancer diagnosis
- Colorectal Cancer Treatments and Studies
- Cancer and Skin Lesions
- Multiple and Secondary Primary Cancers
- Monoclonal and Polyclonal Antibodies Research
- Brain Metastases and Treatment
- Cancer Immunotherapy and Biomarkers
- Advanced Radiotherapy Techniques
- Breast Implant and Reconstruction
Université Paris Cité
2016-2025
Hôpital Saint-Louis
2016-2025
Assistance Publique – Hôpitaux de Paris
2016-2025
Sorbonne Paris Cité
2012-2023
Inserm
2012-2023
Délégation Paris 7
2012-2020
Centre National de la Recherche Scientifique
2010-2019
Institut Curie
2007-2019
Université de Montpellier
2019
Centre Antoine Lacassagne
2019
Abstract Purpose: Inflammatory breast cancer (IBC) is a rare but particularly aggressive form of primary cancer. The molecular mechanisms responsible for IBC are largely unknown. Experimental Design: To obtain further insight into the pathogenesis IBC, we used real-time quantitative reverse transcription (RT)-PCR to quantify mRNA expression 538 selected genes in relative non-IBC. Results: Twenty-seven (5.0%) were significantly up-regulated compared with None down-regulated. 27 mainly encoded...
IBC (Inflammatory Breast cancer) is a rare form of breast cancer with particular phenotype. New molecular targets are needed to improve the treatment this rapidly fatal disease. Given role NF-κB-related genes in cell proliferation, invasiveness, angiogenesis and inflammation, we postulated that they might be deregulated IBC. We measured mRNA expression levels 60 by using real-time quantitative RT-PCR well-defined series 35 IBCs, comparison 22 stage IIB III non inflammatory cancers....
Background In breast cancers, only a minority of patients fully benefit from the different chemotherapy regimens currently in use. Identification markers that could predict response to particular regimen would thus be critically important for patient care. cell lines or animal models, tumor protein p53 (TP53) plays critical role modulating genotoxic drugs. TP53 is activated DNA damage and triggers either apoptosis cell-cycle arrest, which have opposite effects on fate. Yet, studies linking...
Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. A randomized, double-blind, placebo-controlled phase IIB trial assessed sorafenib capecitabine for locally advanced or metastatic human epidermal growth factor receptor 2 (HER2) -negative breast cancer.Patients were randomly assigned to first- second-line 1,000 mg/m(2) orally twice day days 1 14 of every 21-day cycle 400 mg placebo. The primary end point was progression-free survival (PFS).In total, 229...
This study prospectively evaluated the yield of fluorodeoxyglucose positron emission tomography/computed tomography ((18)FDG-PET-CT) in patients with clinical stages II and III breast cancer impact PET-CT results on prognosis.In course 71 months, 254 consecutive (based examination, mammography, magnetic resonance imaging, locoregional ultrasonography) underwent (18)FDG-PET-CT. The was assessed whole population for each American Joint Committee Cancer subgroup. prognostic findings analyzed....
The prognosis of patients with locally advanced breast cancer (LABC) remains poor. We prospectively investigated the impact <sup>18</sup>F-FDG PET/CT at initial staging in this clinical setting and compared performance that conventional distant work-up. <b>Methods:</b> During 60 mo, consecutive LABC (clinical T4 or N2–N3 disease) underwent PET/CT. yield was assessed whole group separately for noninflammatory inflammatory cancer. a approach including bone scanning, chest radiography,...
The choice between chemotherapy and endocrine therapy as first-line treatment for hormone receptor-positive, ERBB2 (also known HER2)-negative metastatic breast cancer is usually based on the presence of clinical features associated with a poor prognosis. In this setting, high circulating tumor cell (CTC) count (≥5 CTCs/7.5 mL) strong adverse prognostic factor overall survival progression-free (PFS).To compare efficacy clinician-driven vs CTC-driven treatment.In CTC arm, patients received or...
Tumor protein p53 (TP53) is mutated in approximately 30% of breast cancers, but this frequency fluctuates widely between subclasses. We investigated the mutation status 572 tumors, classified into luminal, basal and molecular apocrine subgroups. As expected, lowest was observed luminal (26%), highest (88%) tumors. Luminal tumors showed significantly higher substitutions (82 vs. 65%), notably A/T to G/C transitions (31 15%), whereas presented much frequencies complex mutations...
Between 30% and 70% of patients with breast cancer have pre-existing chronic conditions, more than half are on long-term non-cancer medication at the time diagnosis. Preliminary epidemiological evidence suggests that some medications may affect risk, recurrence, survival. In this nationwide cohort study, we assessed association between use diagnosis We included 235,368 French women newly diagnosed non-metastatic cancer. analyzes 288 medications, identified eight positively associated either...
PURPOSE To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, fluorouracil (CMF) in premenopausal women with axillary node-positive operable breast cancer. PATIENTS AND METHODS The International Collaborative Cancer Group (ICCG) conducted large randomized trial which two alternative schedules were used according participating center: CMF1 versus FEC1...
<i>Background:</i> This phase II study was designed to assess the efficacy and safety of gemcitabine in patients with metastatic breast cancer (MBC) previously treated an anthracycline- or anthracenedione-containing regimen as first-line therapy for disease. <i>Patients Methods:</i> Forty-seven MBC were enrolled five French centers. Patients eligible if they had received one prior chemotherapy anthracycline anthracenedione disease, responded that regimen, relapsed at...
The purpose of this study was to prospectively evaluate the role <sup>18</sup>F-FDG PET/CT in patients with stage IIA, IIB, or IIIA breast cancer. <b>Methods:</b> During 56 mo, 131 consecutive large (>2 cm) cancer and clinical (based on examination, mammography, MRI, ultrasonography) underwent PET/CT. nuclear physician unaware results any other procedure (bone scan, chest radiography, liver ultrasound, thoracoabdominal CT scan). <b>Results:</b> Of examined patients, 36 had IIA (34 T2N0 2...